Establishment of an antibody specific for cancer-associated haptoglobin: a possible implication of clinical investigation by Nishino, Kimihiro et al.
広島大学学術情報リポジトリ
Hiroshima University Institutional Repository
Title Establishment of an antibody specific for cancer-associated haptoglobin: a possible implication of clinical
investigation
Auther(s) Nishino, Kimihiro; Koda, Sayaka; Kataoka, Naoya; Takamatsu,Shinji; Nakano, Miyako; Ikeda, Shun; Kamamatsu, Yuka;
Morishita, Koichi; Moriwaki, Kenta; Eguchi, Hidetoshi;
Yamamoto, Eiko; Kikkawa, Fumitaka; Tomita, Yasuhiko;
Kamada, Yoshihiro; Miyoshi, Eiji





Right Copyright (c) 2018 Nishino et al. This is an open-accessarticle distributed under the terms of the Creative
Commons Attribution License 3.0 (CC BY 3.0), which permits
unrestricted use, distribution, and reproduction in




Establishment of an antibody specific for cancer-associated 
haptoglobin: a possible implication of clinical investigation
Kimihiro Nishino1,2,*, Sayaka Koda1,*, Naoya Kataoka1,*, Shinji Takamatsu1, Miyako 
Nakano3, Shun Ikeda1, Yuka Kamamatsu1, Koichi Morishita1, Kenta Moriwaki1, 
Hidetoshi Eguchi4, Eiko Yamamoto2,5, Fumitaka Kikkawa2, Yasuhiko Tomita6, 
Yoshihiro Kamada1 and Eiji Miyoshi1
1Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Suita, 
Osaka, Japan
2Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
3Graduate School of Advanced Sciences of Matter, Hiroshima University, Higashihiroshima, Hiroshima, Japan
4Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
5Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
6Department of Pathology, International University of Health and Welfare, Narita, Chiba, Japan
*These authors contributed equally to this work
Correspondence to: Eiji Miyoshi, email: emiyoshi@sahs.med.osaka-u.ac.jp
Keywords: fucosylation; glycosylation; haptoglobin; glycan antibody; cancer biomarker
Received: May 24, 2017    Accepted: January 20, 2018    Published: January 29, 2018
Copyright: Nishino et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
We previously found that the serum level of fucosylated haptoglobin (Fuc-
Hpt) was significantly increased in pancreatic cancer patients. To delineate the 
mechanism underlying this increase and develop a simple detection method, we set 
out to generate a monoclonal antibody (mAb) specific for Fuc-Hpt. After multiple 
screenings by enzyme-linked immunosorbent assay (ELISA), a 10-7G mAb was 
identified as being highly specific for Fuc-Hpt generated in a cell line as well as for 
Hpt derived from a pancreatic cancer patient. As a result from affinity chromatography 
with 10-7G mAb, followed by lectin blot and mass spectrometry analyses, it was 
found that 10-7G mAb predominantly recognized both Fuc-Hpt and prohaptoglobin 
(proHpt), which was also fucosylated. In immunohistochemical analyses, hepatocytes 
surrounding metastasized cancer cells were stained by the 10-7G mAb, but neither the 
original cancer cells themselves nor normal hepatocytes exhibited positive staining, 
suggesting that metastasized cancer cells promote Fuc-Hpt production in adjacent 
hepatocytes. Serum level of Fuc-Hpt determined with newly developed ELISA system 
using the 10-7G mAb, was increased in patients of pancreatic and colorectal cancer. 
Interestingly, dramatic increases in Fuc-Hpt levels were observed at the stage IV of 
colorectal cancer. These results indicate that the 10-7G mAb developed is a promising 
antibody which recognizes Fuc-Hpt and could be a useful diagnostic tool for detecting 
liver metastasis of cancer.
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INTRODUCTION
It is a well-known fact that the oligosaccharide 
structure on glycoproteins is altered in several pathological 
conditions, including cancer [1]. Fucosylation is the 
attachment of fucose on glycans via α1-3, α1-4, and α1-6 
linkages. Fucosylation is one of the most important types 
of glycosylation associated with cancer and inflammation 
[2]. We previously reported increased levels of fucosylated 
haptoglobin (Fuc-Hpt) in the sera of patients with 
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pancreatic cancer, based on lectin blot analysis using 
Aleuria aurantia lectin (AAL), which recognizes all 
types of fucosylation [3]. To facilitate the quantitative 
measurement of serum Fuc-Hpt levels, we established 
a lectin-antibody enzyme-linked immunosorbent assay 
(ELISA) for Fuc-Hpt [4] and evaluated the lectin-antibody 
ELISA system under various conditions [5]. Based on the 
results of receiver operating characteristic (ROC) analysis, 
we demonstrated that the sensitivity and specificity for 
serum Fuc-Hpt levels for pancreatic cancer diagnosis 
were 85.1% and 82.3%, respectively (area under curve 
[AUC], 0.91). The diagnostic efficacy of this method 
for pancreatic cancer was almost the same as that of 
carbohydrate antigen 19-9 (CA19-9) which is commonly 
used for the diagnosis of pancreatic cancer. Serum Fuc-
Hpt levels increased with the progression of pancreatic 
cancer through its clinical stages and were especially 
high at stage IV [4]. In general, many cancer biomarkers 
such as α-fetoprotein, carcinoembryonic antigen (CEA) 
and CA19-9 are produced by cancer cells themselves. 
However, it remains unknown whether or not Fuc-Hpt is 
produced by pancreatic cancer tissue and/or the liver. Our 
previous studies demonstrated high expression of Fuc-Hpt 
in the human pancreatic cancer cell line PSN-1, but not in 
other pancreatic cancer cell lines [3].
 In contrast, serum Fuc-Hpt levels are observed 
to increase in other cancers and liver diseases [6–8]. A 
combination assay for Fuc-Hpt and CEA is a prognostic 
cancer biomarker for colorectal carcinoma [9]. Serum 
Fuc-Hpt levels increased with liver disease progression 
from normal volunteers, to chronic hepatitis patients, to 
liver cirrhosis patients, and could be a potential predictive 
biomarker for hepatocellular carcinoma [10]. We also found 
that serum Fuc-Hpt is a useful biomarker for non-alcoholic 
steatohepatitis (NASH) especially for the prediction 
of ballooning hepatocytes (characteristic pathological 
observation of NASH) [11, 12]. When we used Pholiota 
squarrosa lectin (PhoSL), which recognizes core fucose 
(α1-6 fucose) more specifically, instead of AAL, in the 
lectin-antibody ELISA, serum levels of each lectin-reactive 
Hpt were not the same [13]. These observations suggest 
that Fuc-Hpt is produced by various kinds of cells, and 
that the fucosylation linkage differs in a disease-specific 
manner. To identify a productive source of Fuc-Hpt and to 
elucidate a mechanism underlying the increase of Fuc-Hpt, 
a specific antibody for Fuc-Hpt is required that can be used 
in immunohistochemical study and/or ELISA. 
 In the present study, we have developed novel 
antibodies specific for Fuc-Hpt with our unique strategy, 
using HCT116 cells in which fucosylation is completely 
absent due to a mutation in the GDP-mannose-4, 
6-dehydratase (GMDS) gene [14] and can be restored with 
L-fucose treatment. The characterization and possible 
clinical usefulness of one of the established antibodies, 
named the 10-7G mAb, were investigated. Furthermore, the 
availability of our preliminary ELISA system using novel 
Fuc-Hpt antibodies was investigated in terms of a diagnostic 
biomarker for pancreatic cancer and colorectal cancer.
RESULTS
Establishment of specific antibodies against 
fucosylated haptoglobin
We purified approximately 1 mg of Hpt from 
conditioned media from Hpt-transfected HCT116 cells 
with or without L-fucose supplementation (fHpt-HCT 
or Non-fHpt-HCT). As shown by the CBB staining in 
Figure 1A, each purified Hpt contained a high amount 
of the 40-kDa Hpt β chain from mature Hpt and a low 
amount of 70-kDa prohaptoglobin (proHpt) (left panel 
in Figure 1A). Western blot analysis using a commercial 
polyclonal antibody (Hpt Ab, Dako) showed that the 
molecular weight of the Hpt β chain in fHpt-HCT was 
slightly higher than that in Non-fHpt-HCT (center panel 
in Figure 1A). AAL blot analysis confirmed complete 
deficiency and restoration of fucosylation in Non-fHpt-
HCT and fHpt-HCT, respectively (right panel in Figure 
1A). Next, we immunized Balb/c mice at 6 weeks of 
age with purified fHpt-HCT, extracted splenocytes four 
weeks after immunization, and generated hybridomas with 
mouse myeloma cells according to a standard procedure. 
Conditioned media from growing hybridomas were 
screened with ELISA as follows. In the first screening, 
we selected hybridomas containing antibodies that showed 
positive reaction to fHpt-HCT and negative reaction to 
Non-fHpt-HCT. Positive clones from the first screening 
were applied to the second screening, in which clones 
producing antibodies that showed positive reaction to Hpt 
derived from a pancreatic cancer patient (PC-Hpt) and 
negative reaction to that derived from a healthy volunteer 
(HV-Hpt) were selected. A few hybridoma clones produced 
antibodies that were highly specific for fHpt-HCT and 
PC-Hpt. After limiting dilution of the hybridomas, seven 
clones producing monoclonal antibodies specific for both 
fHpt-HCT and PC-Hpt were established (Figure 1B). 
Among these antibodies, a monoclonal antibody named 
as 10-7G mAb was characterized in further experiments. 
However, Western blot analysis showed the 10-7G mAb 
predominantly recognized the Hpt α chain whereas 
polyclonal Hpt Ab recognized the Hpt β chain as well 
as Hpt α chain (Figure 1C). Very faint band pf pro-
haptoglobin (proHpt) was observed in Western blot, using 
10-7G mAb. These results indicated that the 10-7G mAb 
recognized the Hpt α chain under reducing condition. 
Characterization of 10-7G mAb by column 
chromatography followed by Western blot and 
mass spectrometry analyses
The 10-7G mAb was not reactive to Hpt derived from 
a healthy volunteer in ELISA (Figure 1B), although the 10-
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7G mAb recognized Hpt α chain in Western blot (Figure 
1C). To examine the reactivity of the 10-7G mAb in native 
conditions, Hpt product was applied to an affinity column 
immobilized with the 10-7G mAb. The results of Western 
blot analyses with Hpt Ab (Dako) showed equal amounts 
of mature Hpt in three fractions (input, flow-through, and 
elution; left panel in Figure 2A), indicating that the 10-
7G mAb did not concentrate mature Hpt before and after 
affinity chromatography. ProHpt detected by the 10-7G 
mAb was enriched by affinity chromatography (center 
panel in Figure 2A) and proHpt was strongly fucosylated 
as judged by AAL lectin blot (right panel in Figure 2A). 
The enrichment of proHpt was verified more clearly when 
a small amount of fHpt-HCT was added to Hpt product 
(center panel in Figure 2B). Additionally, Fuc-Hpt was 
concentrated by affinity chromatography as shown in 
AAL blot analysis (right panel in Figure 2B). These results 
indicate that the 10-7G mAb recognizes Fuc-Hpt as well 
as proHpt in native conditions. To verify the enrichment of 
Fuc-Hpt and/or proHpt by 10-7G-affinity chromatography 
in detail, site-specific structural analysis of N-glycans on 
Hpt was performed (Figure 3). Consistent with our previous 
report, a small amount of di-, tri-, and tetra-antennary 
fucosylated glycans were mainly observed at site 3 (Asn 
211) and to a lesser extent at site 2 (Asn 184) of Hpt 
product. No change was observed in the glycan profile of 
Hpt product with mass spectrometry analyses before and 
after affinity chromatography (Figure 3A), although proHpt 
detected by AAL blot analysis was condensed (Figure 2A). 
However, when a small amount of fHpt-HCT was added to 
Hpt product, highly branched fucosylated glycans derived 
from Fuc-Hpt and/or proHpt contained in fHpt-HCT 
were enriched in the elution fraction following affinity 
chromatography (Figure 3B), consistent with the results 
obtained from the AAL blot analysis shown in Figure 2B. 
These results indicate that the 10-7G mAb predominantly 
recognizes proHpt and /or Fuc-Hpt in native conditions.
Prohaptoglobin is secreted by several kinds of 
cancer cell lines
As shown in Supplementary Figure 1, proHpt was 
increased in the sera of patients with pancreatic cancer. 
To investigate which kinds of cell types produce proHpt, 
Figure 1: Establishment of specific antibodies against fucosylated haptoglobin. (A) Western blot and AAL lectin blot analyses 
on Non-fHpt-HCT and fHpt-HCT purified from conditioned media from Hpt-transfected HCT116 cells. (B) The 10-7G mAb was reacted to 
fHpt-HCT and PC-Hpt (Hpt derived from a pancreatic cancer patient), but not to Non-fHpt-HCT, and HV-Hpt (Hpt derived from a healthy 
volunteer) in ELISA. (C) Western blot analyses of fHpt-HCT, Non-fHpt-HCT with the polyclonal Hpt Ab and the 10-7G mAb.
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Western blot analyses under reducing conditions by the 
Hpt Ab (Dako) and the 10-7G mAb were performed using 
several kinds of pancreatic cancer and hepatocellular 
carcinoma cell lines. As shown in Figure 4, the human 
pancreatic cancer cell line PSN-1 secreted mature Hpt 
(left panel in Figure 4). PSN-1 also secreted a substantial 
amount of proHpt (right panel in Figure 4). Two other 
pancreatic cancer cell lines, PANC-1 and PK-45, did 
not produce both mature Hpt and proHpt. All three 
hepatocellular carcinoma cell lines tested, Huh7, HepG2, 
and Hep3B secreted mature Hpt, although Hpt levels in 
Huh7 and Hep3B cells were smaller than that of HepG2 
cells. In contrast, only HepG2 cells secreted small amount 
of proHpt. Transfectants of Hpt in HCT116 cells produced 
large amounts of Hpt including proHpt. Western blot using 
10-7G mAb showed strong binding to Hpt α chain band. 
Figure 2: Affinity chromatography with the 10-7G mAb followed by Western blot analyses. Western blot analyses with 
Hpt Ab and the 10-7G mAb and AAL blot analysis were performed for three fractions under affinity chromatography with the 10-7G mAb. 
Hpt products (A) and a sample consisting of a mixture of Hpt products and 1% fHpt-HCT purified from Hpt-transfected HCT116 cells (B) 
were used in chromatography. To detect Hpt α chain with Western blot, 15% SDS-PAGE was used. Silver staining was shown as loading 
control. Detail procedure was described in Materials and Methods.
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These results suggest that certain kinds of pancreatic 
cancer and hepatocellular carcinoma cell lines could 
produce proHpt.
Hepatocytes surrounding metastasized 
pancreatic cancer cells produce the 10-7G mAb-
reacting Hpt
To identify which kinds of cell types mainly produce 
Fuc-Hpt and/or proHpt in pancreatic cancer patients, 
we performed immunohistochemical analysis with the 
10-7G mAb using various tissues. As shown in Figure 
5, weak expression of mature Hpt was detected by the 
monoclonal anti-Hpt antibody (Abcam) in both primary 
and metastasized pancreatic cancer cells (Figures 5A 
and 5C). Hepatocytes surrounding metastatic pancreatic 
cancer tissue and normal hepatic tissue strongly expressed 
mature Hpt (Figure 5C and 5E). In contrast, neither 
primary nor metastasized pancreatic cancer cells were 
stained by the 10-7G mAb (Figure 5B and 5D). Strikingly, 
hepatic tissues surrounding the metastatic pancreatic 
cancer tissue were stained by the 10-7G mAb, whereas 
normal hepatocytes were not stained (Figure 5D and 5F). 
These results suggest that pancreatic cancer cells that have 
metastasized to the liver promote the production of Fuc-
Hpt and/or proHpt (cancer associated Hpt) from adjacent 
hepatocytes. In the case of hepatocellular carcinoma, 
tumor cells were stained with both Hpt Ab and the 10-
7G mAb (Figure 5G and 5H), indicating that hepatoma 
cells produce both mature Hpt and Fuc-Hpt. In a case of 
liver metastasis of colorectal cancer, strong staining with 
the 10-7G mAb was observed in adjacent lesion of the 
metastasis and the staining level was decreased in distant 
lesion of the metastasis (Supplementary Figure 2). 
Figure 3: Affinity chromatography with the 10-7G mAb followed by site-specific analyses of N-glycans on haptoglobin 
by mass spectrometry. The ratio of various N-glycans at each site on haptoglobin was calculated from the results of mass spectrometry 
for three fractions (input, flow-through, elution) under affinity chromatography with the 10-7G mAb. Hpt products (A) and a sample 
consisting of a mixture of Hpt products + 1% fHpt-HCT purified from Hpt-transfected HCT116 cells (B) were used in chromatography. 
The arrow indicates highly branched N-glycans on Fuc-Hpt and/or proHpt derived from HCT116 cells. Site 1: Asn 184; Site 2: Asn 207; 
Site 3: Asn 211; Site 4: Asn 241. For the abbreviations of N-glycan structures on the glycopeptides, the simplified notation was used. For 
example, the peptide containing the tri-antennary N-glycan with one Fuc residue is represented as “3-F.” The first numeral indicates the 
branch number (tri-antennary in this case) or LAcNAc number (3 LAcNAc in this case), and “F” indicates one Fuc residue. “0” denotes 
the absence of Fuc.
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Serum Fuc-Hpt levels determined with our 
newly developed ELISA were increased in 
patients with pancreatic cancer and colon cancer
We previously reported that serum Fuc-Hpt levels 
determined with lectin-antibody ELSA were a diagnosis 
biomarker for pancreatic cancer [5] and a prognostic 
biomarker for colorectal cancer [9]. Therefore, we 
measured serum Fuc-Hpt levels of those patients with 
our newly developed ELISA. First, we compared Fuc-
Hpt levels determined with 2 different ELISA methods. 
As shown in Supplementary Figure 3, The correlation 
between 2 kinds of methods was not statistically 
significant, but tended to be slightly similar. Interestingly 
serum Fuc-Hpt levels determined with our newly 
developed ELISA were significantly increased in patients 
with pancreatic and colorectal cancer patients (Figure 6). 
A few cases of chronic pancreatitis showed high levels 
of Fuc-Hpt determined with newly developed ELISA. In 
cases of colorectal cancer, the levels were significantly 
increased at clinical stage IV, especially in liver metastasis 
(Figure 7A). In contrast, significant increases in Fuc-Hpt 
levels determined with newly developed ELISA were 
observed in clinical stage III and IV of pancreatic cancer 
(Figure 7B). 
DISCUSSION
In the present study, we have developed antibodies 
specific for Fuc-Hpt using a unique screening system 
Figure 4: Western blot analysis of proHpt with the 10-7G mAb in conditioned media from human pancreatic cancer 
and hepatocellular carcinoma cell lines. Thirty micrograms of secreted proteins in conditioned media were electrophoresed on 
15% SDS-PAGE gels, followed by Western blot analyses with Hpt Ab and the 10-7G mAb. Samples collected from HCT116 cells with or 
without L-fucose treatment (HCT116 f and HCT116 nf, respectively) were used as positive controls. Each band showed Hpt-related protein 
as shown at right side. Silver staining was shown as loading controls.
Oncotarget12738www.impactjournals.com/oncotarget
with GMDS mutant HCT116 cells and characterized one 
of the established antibodies, named the 10-7G mAb. 
We demonstrated that the 10-7G mAb predominantly 
recognized Hpt α chain as well as proHpt in the reducing 
conditions and that this antibody recognized both Fuc-Hpt 
and proHpt in native conditions. Additionally, we found 
that the serum level of a novel Fuc-Hpt determined by 
10-7G mAb was increased in patients with pancreatic and 
colorectal cancer at the advanced stage and that expression 
of Fuc-Hpt was not observed in primary or metastasized 
pancreatic cancer cells but observed in hepatocytes 
surrounding metastatic pancreatic cancer.
Figure 5: Immunohistochemical study of Fuc-Hpt in pancreatic cancer and liver tissue. Immunohistochemical staining was 
performed with both the Hpt mAb and the 10-7G mAb as described in the Material and Methods section. (A) and (B), primary pancreatic 
cancer; (C) and (D), metastatic pancreatic cancer to the liver; (E) and (F), normal hepatic tissue; (G) and (H), hepatocellular carcinoma 
(HCC). Photographs were taken using a 4× objective. Scale bar, 500 µm. Arrow showed metastatic pancreatic cancer in the liver and 
arrowhead showed positive staining of each antibody.
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Mature human Hpt, which is produced mainly 
by the liver and functions primarily to bind free 
plasma hemoglobin released from erythrocytes due to 
intravascular hemolysis, consists of an α and β chain 
heterodimer combined by disulfide bonds as a basic unit 
which eventually dimerizes or multimerizes [15–18]. The 
β chain possesses all of the four N-glycans in mature Hpt 
at the sites of Asn 184, 207, 211, and 241, where fucose 
residues are additionally bound by fucosyltransferases in 
cancer patients [10, 19–21]. ProHpt is a premature form 
of haptoglobin containing the α and β subunits within a 
single polypeptide chain; proHpt is separated and joined 
again via disulfide bonds in the maturation process. 
The separation at the junction of the α and β chains is 
catalyzed by a serine protease named complement C1r-like 
proteinase (C1r-LP) in the endoplasmic reticulum, before 
the protein enters the Golgi complex [22–25]. 
The 10-7G mAb showed a positive reaction to PC-
Hpt and a negative reaction to HV-Hpt (Figure 1B). This is 
partially due to the relatively higher level of proHpt in PC-
Hpt than in HV-Hpt (Supplementary Figure 1). Since C1r-
LP activity is primarily high in the liver, proHpt is scarcely 
produced in hepatocytes under physiological conditions. 
In fact, normal liver tissue was not stained with the 10-7G 
mAb recognizing proHpt (Figure 5F). It has been reported 
that various tissues including the lung, arteries, kidneys, 
skin, and leukocytes express extra-hepatic Hpt [26–30]. 
Therefore, proHpt, which is detected in the sera of healthy 
volunteers, might be produced by non-hepatic tissues/
cells, where both Hpt and C1r-LP expression is relatively 
low. On the other hand, the 10-7G mAb positively stained 
hepatic tissue surrounding metastatic pancreatic cancer 
(Figure 5D) as well as primary hepatoma cells (Figure 
5H), where mature Hpt is primarily produced. However, 
we could not demonstrate that this staining is dependent 
on Fuc-Hpt and/or proHpt. This is the limitation of 
immunostaining of 10-7G mAb. 
The binding epitope of proHpt for the reactivity of 
the 10-7G mAb still remains to be identified. The results 
of present experiments indicate that haptoglobin α chain, 
which does not possess N-glycans, is a critical part for the 
binding of the 10-7G mAb which recognizes Fuc-Hpt and 
proHpt. While the detailed molecular mechanisms remain 
unknown, conformational changes following fucosylation 
and/or N-glycan branching may affect the binding between 
α chain and the 10-7G mAb.  
Recently, various functions of mature Hpt other than 
its main role of binding free hemoglobin in the circulation 
have been described, including immune modulation 
[31–33], angiogenesis [34], arterial restructuring [35], 
cell proliferation and cell migration [36]. In contrast, 
limited information about the function of proHpt is 
Figure 6: Determination of serum Fuc-Hpt levels with new ELISA system, using 10-7G mAb. Serum Fuc-Hpt levels in 
healthy volunteers (HV), colorectal cancer patients (CRC), chronic pancreatitis patients (CP) and pancreatic cancer patients (PC), were 
measured with new ELISA system with 10-7G mAb. *P < 0.05. **P < 0.01. 
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available. Oh et al. recently reported that proHpt plays 
a pivotal role in angiogenesis through the upregulation 
of vascular endothelial growth factor (VEGF) and 
VEGF receptor 2 expression in endothelial cells [37]. 
The present study demonstrated increased proHpt levels 
in the sera of patients with pancreatic cancer (Figure 6 
and Supplementary Figure 1), consistent with the study 
of Oh et al. reporting an increase in serum proHpt levels 
in patients with hepatoma, suggesting a role for proHpt 
in cancer progression [37]. Therefore, proHpt could be 
considered as cancer-associated Hpt. 
Our preliminary ELISA kit measuring Fuc-Hpt 
showed relatively similar results of our previous reports 
by lectin-antibody ELISA while there is slight correlation 
of 2 types of Fuc-Hpt measured by different methods 
(Supplementary Figure 2). Basically, serum Fuc-Hpt 
level determined with 10-7G mAb is increased at the 
advanced stage, especially liver metastasis. In certain 
cases of pancreatic cancer, Fuc-Hpt levels were increased 
at clinical stage II and III. However, micro-metastasis 
at different organs, which were not detected with image 
diagnosis such as CT or MRI would be observed at clinical 
stage II and III of pancreatic cancer. Therefore, follow-
up studies on serum Fuc-Hpt levels should be performed 
before/after surgical treatment. Since antibody is much 
superior to lectin in terms of specificity and reproducibility 
in general, our newly developed Fuc-Hpt ELISA could be 
applied to clinical diagnosis test for detecting early liver 
metastasis. However, we could not demonstrate that serum 
level of Fuc-Hpt using a novel ELISA kit is dependent on 
Fuc-Hpt and/or proHpt. This is the limitation of ELISA of 
10-7G mAb.
In conclusion, we succeeded in the establishment 
of a monoclonal antibody recognizing Fuc-Hpt and 
proHpt and investigated the clinical availability with 
immunohistochemistry and ELISA. The 10-7G mAb 
might be a promising tool to predict liver metastasis of 




All clinical samples were obtained from Osaka 
University affiliated hospitals or Osaka Medical Center for 
Cancer and Cardiovascular Diseases. Sera from healthy 
volunteers who received physical checkups or patients 
with pancreatic cancer, chronic pancreatitis and colorectal 
cancer before medical interventions were collected and 
kept frozen at –80° C until use. Tissue samples obtained 
from patients with primary or metastatic pancreatic cancer 
and hepatocellular carcinoma at primary surgery were 
embedded in paraffin sections and kept at room temperature 
until use. This study was approved by the ethics committee 
of Osaka University Hospital (No. 11300-3), and was 
conducted in accordance with approved guidelines. Written 
informed consent was obtained from all subjects in this 
study at the time of enrollment or blood sampling.
Haptoglobin products
Hpt product purified from pooled plasma of several 
healthy individuals was purchased from Japan Blood 
Products Organization (Tokyo, Japan).  
Cell culture
The human colon cancer cell line HCT116; human 
pancreatic cancer cell lines PANC-1, PK-45, and PSN-
1; and human hepatocellular carcinoma cell lines Huh7, 
HepG2, and Hep3B were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA) or the 
Cell Resource Center for Biomedical Research, Institute 
Figure 7: Relationship of clinical stage and serum Fuc-Hpt levels determined with new ELISA system, using 10-
7G mAb. Serum Fuc-Hpt levels were plotted in terms of clinical stage of colorectal cancer (CRC) (A) and pancreatic cancer (PC) 
(B). Horizontal grey lines indicate the mean values of Fuc-Hpt in each group. *P < 0.05. **P < 0.01. 
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of Development, Aging and Cancer, Tohoku University 
(Sendai, Japan). They were maintained at 37° C in a 
humidified atmosphere with 5% CO2 and 95% air in 
RPMI 1640 (Sigma-Aldrich Corp., St. Louis, MO), 
supplemented with 10% heat-inactivated fetal bovine 
serum (Life Technologies Corp., Carlsbad, CA), 100 units/
ml of penicillin and 100 µg/ml of streptomycin (Nacalai 
Tesque Inc., Kyoto, Japan). 
Purification of haptoglobin from conditioned 
media from HCT116 cells, or from human sera
Because HCT116 cells have a mutation in the 
fucosylation regulatory gene encoding GDP-mannose-4,6-
dehydratase (GMDS) [14], all glycoproteins produced from 
HCT116 cells lack fucosylation. In contrast, fucosylation 
is restored with L-fucose treatment. An expression vector 
(pcDNA/hygro) with human Hpt encoding Hpt α2β (Hpt2) 
[38] was transfected into HCT116 cells. Cells expressing 
high levels of Hpt were cloned following treatment with 
Hygromycin B (Wako Pure Chemical Industries Ltd., 
Osaka, Japan). Non-fucosylated Hpt (Non-fHpt-HCT) 
was purified from conditioned media from Hpt-transfected 
HCT116 cells using an affinity chromatography column 
coupled with a rabbit polyclonal anti-Hpt antibody (Hpt 
Ab, Dako, Glostrup, Denmark) as previously described 
[3]. Fucosylated Hpt (fHpt-HCT) was purified by the 
same procedure after the addition of 1 mM L-fucose 
(Wako) into the media from HCT116 cells. Hpt purified 
from the serum of a healthy volunteer (HV-Hpt) or from 
a patient with pancreatic cancer (PC-Hpt) was obtained 
using affinity chromatography as well. In the affinity 
chromatography, PBS was used for washing columns and 
diluting samples.
Hybridoma production and the establishment of 
monoclonal antibodies against Fuc-Hpt 
Balb/c mice were immunized at 6 weeks of age by 
an intramuscular injection of 200 µg of purified fHpt-
HCT. Additional immunizations of 50 µg of purified fHpt-
HCT were administered twice every two weeks, and the 
splenocytes were extracted following confirmation of a rise 
in antibody titer against Hpt. All experimental protocols 
and animal maintenance procedures used in this study were 
approved by the Ethics Review Committee for Animal 
Experimentation of Osaka University Graduate School of 
Medicine (IACUC 25038). The splenocytes were fused 
with mouse myeloma cells to make hybridomas according 
to a standard procedure. Conditioned media from growing 
hybridomas were screened using ELISA, as described 
below. Selection was performed based on a positive reaction 
to fHpt-HCT and a negative reaction to Non-fHpt-HCT in 
the first screening, and a positive reaction to PC-Hpt and a 
negative reaction to HV-Hpt in the second screening.
Coomassie Brilliant Blue (CBB) staining, silver 
staining, Western blot, and lectin blot analysis 
Equal amounts of purified proteins or secreted 
proteins in conditioned media from each cancer cell line, 
or equal aliquots of sera were denatured in SDS sample 
buffer with 2-mercaptoethanol by boiling at 95° C, 
resolved on 10% SDS-PAGE gels and separated by 
electrophoresis. 15% SDS-PAGE was used to detect 
Hpt α-chain with Western blot. For CBB staining 
or silver staining, gels were stained and destained 
according to a standard procedure. For Western blot or 
lectin blot analysis, the proteins were transferred onto 
PVDF membranes and the membranes were blocked 
with 5% skim milk in Tris-buffered saline containing 
0.05% Tween 20 (TBS-T) or 3% BSA in TBS-T. The 
membranes were incubated with Hpt Ab (Dako), the 
established mouse monoclonal 10-7G antibody (10-
7G mAb), or biotinylated AAL (J-OIL MILLS Inc., 
Tokyo, Japan) and then incubated with HRP-conjugated 
secondary antibody (Promega Corp., Madison, WI) 
or streptavidin-HRP (Abcam plc., Cambridge, UK) as 
previously described [3].  After each incubation step, the 
membranes were washed with TBS-T three times for 10 
min each. Protein bands were visualized by developing 
the blots with Chemiluminescent Reagent ImmunoStar 
Zeta (Wako, Osaka, Japan) using ImageQuant LAS 
4000mini (GE Healthcare, Buckinghamshire, UK). The 
cleavage of N-glycans in purified Hpt was performed 
using glycopeptidase F (Peptide N-glycosidase F, Takara 
Bio Inc., Shiga, Japan) according to the manufacturer’s 
protocol. As a negative control, an equal amount of 
distilled water was added to the samples instead of the 
enzyme. To analyze smaller proteins such as haptoglobin 
α chain, 15% SDS-PAGE gels were used. 
Site-specific analyses of N-glycans on 
haptoglobin by mass spectrometry
The detailed procedure is as previously described 
[19]. Briefly, 50 µg of Hpt was digested with trypsin and 
endoprotease Glu-C after reduction (dithiothreitol) and 
alkylation (iodoacetamide). Glycopeptides were enriched 
using a Sepharose CL4B column. For de-sialylation, 
the glycopeptides were dissolved in 2 M acetic acid 
and incubated for 2 h at 80° C. Dried glycopeptides 
were dissolved in 12 µL of 0.08% formic acid and were 
subjected to liquid chromatography electrospray ionization 
(LC-ESI) MS analyses. Analytical conditions for LC-
ESI MS and the data analysis procedure for relative 
quantitation have been previously described [39]. Briefly, 
glycopeptides were separated using an octadecyl silica 
(ODS) column under specific gradient conditions at a 
flow rate of 50 µL/min using an Accela HPLC system 
(Thermo Fisher Scientific Inc., Waltham, MA). The 
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mobile phases were solvent A (0.08% formic acid) and 
solvent B (0.15% formic acid in 80% acetonitrile). The 
elution fraction was introduced continuously into an ESI 
source, and glycopeptides were analyzed by LTQ Orbitrap 
XL (Thermo) in positive ion mode. For the relative 
quantitation of site-specific N-glycans, the peak intensity 
of quadruply charged ions [M+4H]4+ for site 1 (Asn 184) 
or 4 (Asn 241) and triply charged ions [M+3H]3+ for site 2 
(Asn 207) or site 3 (Asn 211) on an average mass spectrum 
were used (Xcalibur software ver. 2.0.7; Thermo).
Immunohistochemistry
Tissue samples fixed in 10% formaldehyde and 
embedded in paraffin sections (4 μm thick) were de-
paraffinized in xylene and rehydrated in graded ethanol. 
Endogenous peroxidase activity was blocked by incubating 
3% hydrogen peroxide in 100% methanol. After blocking 
non-specific protein binding with Protein Block Serum-
Free (Code X0909, Dako) for 10 min at room temperature 
(RT), the sections were incubated with 3.3 µg/mL of a 
mouse monoclonal anti-Hpt antibody (Abcam) or 5 µg/
mL of the 10-7G mAb diluted in Antibody Diluent (Code 
S0809, Dako) overnight at 4° C. The sections were then 
incubated with EnVision+ System HRP-Labeled Polymer 
Anti-Rabbit (Code K4002, Dako), or Anti-Mouse (Code 
K4000, Dako) for 30 min at RT. After each incubation 
step, the sections were washed with PBS three times for 
10 min each. Subsequently, the sections were incubated 
with the Liquid DAB+ Substrate Chromogen System 
(Code 3467, Dako) for 5 min to develop the stain. Finally, 
the sections were counterstained with haematoxylin, 
dehydrated, and mounted. Pictures were taken with a BZ-
9000 microscope (KEYENCE, Tokyo, Japan).
ELISA
For hybridoma screening, conditioned media from 
mouse hybridomas or control fluids were added on Nunc 
Maxisorp 96-well immunoplates (Thermo) pre-coated 
with a rabbit anti-mouse IgG antibody and incubated for 
1 h at RT. Purified Hpt were loaded on the plate at 100 ng/mL 
for 1 h at RT followed by solid-phase blocking. HRP-
conjugated Hpt Ab (diluted 1:2,000) was added to the plate 
and incubated for 1 h at RT. After each incubation step, the 
plate was washed with PBS three times. The color was 
developed using an o-phenylenediamine dihydrochloride 
tablet as the chromogen, and the optical density was 
measured at 492 nm by an iMarkTM Microplate Absorbance 
Reader (Bio-Rad Laboratories Inc. Philadelphia, PA). For 
development of a new ELISA kit to measure Fuc-Hpt, the 
10-7G mAb was coated on 96-well plate. After blocking 
with TBS containing 10% Block Ace (DS Pharma 
Biomedical, Osaka, Japan) 5000 times diluted serum 
samples were loaded. The plate was incubated for 1 h at RT 
and then washed with TBS containing 0.05% Tween 20. 
HRP-conjugated the 3-25-1C mAb, which is another 
established antibody specific for Fuc-Hpt was added to 
each well and incubated for 1 h at RT. The development 
procedure was the same as described above.
Statistical analysis
The statistical analysis was performed using JMP 
Pro 12.0 software (SAS Institute Inc., Cary, NC). The 
statistical analysis included descriptive statistics, analysis 
of variance, the Wilcoxon and Kruskal-Wallis tests, and 
Spearman R correlation analysis. As the measurement data 
from 10-7G mAb ELISA and lectin-antibody ELISA did 
not show Gaussian distribution; these parameters were 
common log-transformed before correlation analysis. 
Differences were considered to be statistically significant 
at a P-value < 0.05. 
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